Report : Asia Pacific Overactive Bladder Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)
At 3.7% CAGR, the Asia Pacific Overactive Bladder Treatment Market is speculated to be worth US$ 1,082.25 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific overactive bladder treatment market was valued at US$ 871.48 million in 2022 and is expected to reach US$ 1,082.25 million by 2028, registering a CAGR of 3.7% from 2022 to 2028. Robust pipeline of drugs and successive launch of novel therapies and increasing number of mergers and acquisitions are the critical factors attributed to the Asia Pacific overactive bladder treatment market expansion.
Through mergers and acquisitions (M&A) companies can gain a competitive edge by entering into new markets and acquiring new technologies. The ongoing mergers and acquisitions in the overactive bladder treatment market are creating growth opportunities for the companies. In July 2021, Uro Medical strengthened its urology portfolio with the acquisition of Micron Medical, which offers wirelessly powered, injectable, microtechnology neurostimulators focused on treating overactive bladder. These neurostimulators, which can be easily incorporated into patients’ daily lives, offer a convenient, safe, minimally invasive, and cost-effective urological treatment option. In February 2021, Axonics Modulation Technologies, Inc., a medical technology company, acquired Contura Ltd. and its proprietary product, Bulkamid, which is a urethral bulking agent for women with stress urinary incontinence (SUI). Axonics produces and markets novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition of Contura Ltd. provides it an opportunity to expand its SNM business across the world and serve the large, highly underpenetrated SUI market. The company plans to offer urogynecologists and urologists a complete suite of clinically differentiated incontinence solutions to treat their patients.
On the contrary, recalls of therapeutic drugs hurdles the growth of Asia Pacific overactive bladder treatment market.
Based on pharmacotherapy, the Asia Pacific overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment held 37.7% market share in 2022, amassing US$ 328.35 million. It is projected to garner US$ 413.81 million by 2028 to expand at 3.9% CAGR during 2022–2028.
Based on disease type, the Asia Pacific overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held 59.2% market share in 2022, amassing US$ 515.91 million. It is projected to garner US$ 651.70 million by 2028 to expand at 4.0% CAGR during 2022–2028.
Based on country, the Asia Pacific overactive bladder treatment market is segmented into China, Japan, India, South Korea, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that the China captured 29.8% market share in 2022. It was assessed at US$ 259.44 million in 2022 and is likely to hit US$ 331.17 million by 2028, exhibiting a CAGR of 4.2% during the forecast period.
Key players dominating the Asia Pacific overactive bladder treatment market are AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd, among others.
- In Feb 2022, InterStim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.
- In 2021, Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org